CEO
HabitNu
I have been studying cellular and molecular causes of obesity and diabetes at the
The University of Chicago for the last 12 years. During my research career, I have
closely observed the personal struggles of individuals to manage their diabetes.
Every one out of ten Americans has type-2 diabetes and every one out of three has
prediabetes. We developed the HabitNu program to prevent or reverse type 2
diabetes and hypertension.
HabitNu is fully recognized by the CDC based on its outcomes. HabitNu is eligible
for reimbursement from several commercial health plans, Medicaid and Medicare.
Several thousand participants have benefitted from the HabitNu Program.
Disclosure information not submitted.
Sunday, September 11, 2022
8:30 AM – 4:00 PM MST